2017
DOI: 10.1016/j.kisu.2017.04.001
|View full text |Cite|
|
Sign up to set email alerts
|

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
635
3
48

Year Published

2018
2018
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 1,370 publications
(691 citation statements)
references
References 173 publications
(240 reference statements)
5
635
3
48
Order By: Relevance
“…In view of this complex interplay, it is worth mentioning that we observed a 3.5-times lower Δ T 50 -time in the intervention group compared to the rescue group, although the change was only of small magnitude and the difference statistical insignificant. However, it might be thinkable, that the “mineralization paradox [41] – the inverse relation of bone mineralization and vascular calcification – in dialysis patients is partly driven by the therapeutic compensation of acidosis with high bicarbonate dialysate concentrations [42-44] in combination with vitamin D treatment [11] and insufficient control of hyperphosphatemia [45]. Furthermore, high serum bicarbonate levels are associated with higher mortality in dialysis [46] and non-dialysis CKD populations [47].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In view of this complex interplay, it is worth mentioning that we observed a 3.5-times lower Δ T 50 -time in the intervention group compared to the rescue group, although the change was only of small magnitude and the difference statistical insignificant. However, it might be thinkable, that the “mineralization paradox [41] – the inverse relation of bone mineralization and vascular calcification – in dialysis patients is partly driven by the therapeutic compensation of acidosis with high bicarbonate dialysate concentrations [42-44] in combination with vitamin D treatment [11] and insufficient control of hyperphosphatemia [45]. Furthermore, high serum bicarbonate levels are associated with higher mortality in dialysis [46] and non-dialysis CKD populations [47].…”
Section: Discussionmentioning
confidence: 99%
“…Derangements of calcium and phosphorus homeostasis, parathyroid hormone and metabolic bone disease are summarized as the “chronic-kidney-disease – mineral and bone disorder – CKD-MBD,” a syndrome associated with severe vascular calcification [11]. Vascular calcification is strongly related with morbidity and mortality in CKD patients [12, 13].…”
Section: Introductionmentioning
confidence: 99%
“…Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) was the largest and most important study to date addressing the impact of this medication on cardiovascular outcomes in dialysis patients [47]. Because EVOLVE did not meet the primary endpoint of reducing the risk of death or clinically important vascular events in dialysis patients, and also due to the high cost of the drug, the KDIGO CKD-MBD 2017 update did not recommend cinacalcet as a first-line therapy for SHPT in this population, rather listing the PTH-lowering therapies in alphabetical order [3]. Recent studies in CKD patients exploring some of the pleiotropic effects of active vitamin D in this population were deceiving.…”
Section: Another Paradigm Shift In Vdra Use For Shptmentioning
confidence: 99%
“…The altered mineral metabolism in CKD is thought to contribute to the high mortality noted in this population. While this review focuses on the treatment of secondary hyperparathyroidism (SHPT) with active vitamin D, it is important to remember that concomitant management of associated hyperphosphatemia and hypocalcemia and avoidance of hypercalcemia are imperative, as recommended by multiple sources, more recently by the updated 2017 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-Mineral and Bone Disorder (CKD-MBD) guidelines [3]. …”
Section: Introductionmentioning
confidence: 99%
“…It is not yet clear to what extent IV or oral iron use will be needed to support effective erythropoiesis in patients receiving these agents. The optimal role of newer, oral iron-containing phosphate binders, one of which (i.e., ferric citrate) is associated with substantial systemic iron absorption, has not yet been incorporated into evidence-based recommendations [32, 82]. …”
Section: Future Directionsmentioning
confidence: 99%